Back to results
US 5,399,355 AGranted
Agent for transdermal administration containing ergoline derivatives
AssigneeSchering Corporation
InventorsJutta Riedl, Clements Gunther, Ralph Lipp
Life of this patent
Estimating the term…
Abstract
An agent for transdermal administration contains ergoline derivatives optionally in combination with one or more penetration-enhancing agent or agents.
Claims13
A transdermal therapeutic system which comprises:
- a) an impermeable covering layer;
- adhering to the covering layer, a permeable pharmaceutical agent layer comprising an ergoline derivative selected from the group consisting of 2-bromolisuride, terguride, proterguride and physiologically acceptable acid salts thereof, a pharmaceutically acceptable carrier effective for transdermal administration and, optionally, a transdermally effective penetration-enhancing agent,
- wherein the pharmaceutical agent layer contains a polyacrylate skin contact adhesive such that it is self-adhesive or is covered over or surrounded by a polyacrylate skin contact adhesive, which can optionally contain penetration-enhancing agents;
- and a removable protective layer, or
- b) an impermeable covering layer,
- a pharmaceutical agent reservoir on or in the covering layer, comprising an ergoline derivative selected from the group consisting of 2-bromolisuride, terguride, proterguride and physiologically acceptable acid salts thereof, a pharmaceutically acceptable carrier effective for transdermal administration and, optionally, a transdermally effective penetration-enhancing agent;
- a polymeric layer permeable for the components of the pharmaceutical agent reservoir;
- a permeable polyacrylate skin contact adhesive layer optionally containing penetration-enhancing agents;
- and
- a removable protective layer.
7 more elements
A transdermal therapeutic system which comprises:
- a) an impermeable covering layer;
- adhering to the covering layer, a permeable pharmaceutical agent layer comprising an ergoline derivative, selected from the group consisting of 2-bromolisuride, terguride, proterguride and physiologically acceptable acid salts thereof, a pharmaceutically acceptable carrier effective for transdermal administration and a transdermally effective penetration-enhancing agent,
- wherein the pharmaceutical agent layer contains a skin contact adhesive such that it is self-adhesive or is covered over or surrounded by a skin contact adhesive, which can, optionally, contain penetration-enhancing agents;
- and a removable protective layer, or
- b) an impermeable covering layer,
- a pharmaceutical agent reservoir on or in the covering layer, comprising an ergoline derivative selected from the group consisting of 2-bromolisuride, terguride, proterguride and physiologically acceptable acid salts thereof, a pharmaceutically acceptable carrier effective for transdermal administration and a transdermally effective penetration-enhancing agent;
- a polymeric layer permeable for the components of the pharmaceutical agent reservoir;
- a permeable skin contact adhesive layer containing penetration-enhancing agents;
- and
- a removable protective layer, wherein the penetration-enhancing agent is 1,2-propanediol, menthol, dexpanthenol, benzyl alcohol, lauryl alcohol, isocetyl alcohol, cetyl alcohol, mineral oil, lauric acid, isopalmitic acid, isostearic acid, oleic acid, or a dicarboxylic acid diester of the formula
- R'OCO(CH.sub.2).sub.m COOR'
- in which:
- m is 4 to 8 and
- R' is alkyl of up to 6 carbon atoms.
11 more elements
Dependencies are inferred from the claim text.